Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.

Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS.

Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.

2.

PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.

Kurz SC, Cabrera LP, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee EQ, Reardon DA, Wen PY.

Neurology. 2018 Oct 2;91(14):e1355-e1359. doi: 10.1212/WNL.0000000000006283. Epub 2018 Aug 31.

PMID:
30171077
3.

Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?

Kurz SC, Wen PY.

Curr Treat Options Neurol. 2018 Apr 18;20(5):14. doi: 10.1007/s11940-018-0499-0. Review.

PMID:
29666934

Supplemental Content

Support Center